We audited patients with anaphylaxis to muscle relaxants during anaesthesia referred to the Department of Anaesthesia at the Royal Adelaide Hospital between the start of 2000 and the end of 2009. Of the 220 patients tested during this period, 43 had a positive intradermal test to the muscle relaxant given during their anaesthetic. The majority of these were to rocuronium and suxamethonium. Where rocuronium was the index agent, 65% of patients cross-reacted with another relaxant and 29% of patients with suxamethonium as their index agent demonstrated cross-reaction with another relaxant.
Data on allergy associated with anaesthesia is infrequently published and trends within these data vary between countries 1 . The last Australian data were from New South Wales in 1993 2 . Data from France have been published most frequently [3] [4] [5] [6] [7] , but there are a few reports from other regions. The incidence of anaphylaxis to anaesthetic drugs in Australia is estimated as 1:10,000-1:20,000 anaesthetics 2 , but is reported more frequently, at about 1:5000 anaesthetics, in some other countries 1, [8] [9] [10] . Anaphylaxis is an event anaesthetists are likely to see only occasionally during their career, although it is important as, even when appropriately treated, it has a mortality of up to 10% 1, [9] [10] [11] [12] [13] [14] .
The most common drug group implicated is muscle relaxants [1] [2] [3] 8, 11, [13] [14] [15] [16] [17] . The frequency of anaphylaxis with any drug is related to the amount of exposure and the allergenic tendency of that drug. The Australian data from 1993 suggested differences in allergenic tendency and risk of anaphylaxis with the different muscle relaxants in the New South Wales population.
The current audit was undertaken to identify the relaxants causing anaphylaxis in the South Australian population and to estimate the risk of anaphylaxis associated with muscle relaxants in common use in South Australia.
METHODS
The Royal Adelaide Hospital was one of two public hospitals in South Australia that were taking referrals for allergy testing following anaesthetic anaphylaxis during the ten-year audit period from 1 January 2000 to 31 December 2009. We collected data by reviewing the case notes of all patients referred to the Royal Adelaide Hospital who tested positive for a muscle relaxant as the cause of anaphylaxis during this ten-year period.
The referrals came from 11 public and six private hospitals in South Australia. One referral came from another state where a patient had been anaesthetised while on holiday and had returned to Adelaide for testing. Generally, referrals were made by the anaesthetist involved when the reaction occurred. All patients referred were accepted for testing irrespective of symptom pattern and severity or the results of mast cell tryptase levels taken at the time of the event.
Intradermal testing was used to diagnose allergy using standard dilutions (Table 1) . Testing was performed on the volar aspect of the forearm. A bleb of 5 mm in diameter was raised with each intradermal injection and the tests were read at 20 minutes. A positive test was recorded where the wheal was larger than the area of the original injection and was documented as a measurement of wheal/flare in mm. Further intradermal tests were then performed to Not all muscle relaxants were tested on all patients. Serial dilutions were not used.
As an estimate of the frequency of use of the various muscle relaxants available, the pharmacy at the Royal Adelaide Hospital supplied purchasing data for the relaxants most commonly used during the audit period. Unfortunately the use data were not available from the other public or the private hospitals. These Royal Adelaide Hospital data were used to estimate the clinical use of each drug by dividing into standard doses (vials). This was compared with the incidence of anaphylaxis to each drug.
This audit had the approval of the Royal Adelaide Hospital ethics committee (24 January 2011).
RESUlTS
Two hundred and twenty patients were tested for allergy relating to anaesthetics during the ten-year audit period.
Forty-three patients had a positive skin test to the muscle relaxant given during their anaesthetic. The age of these 43 patients ranged from 19-81 years, with a median age of 49 years (Figure 1 ). The gender distribution showed a 3:1 female to male ratio.
The majority of referrals came from private hospitals in Adelaide. Referral from the Royal Adelaide Hospital was 23% of the total number. The sources of referral are shown in Figure 2 . Figure 3 illustrates the index agents responsible for anaphylaxis to muscle relaxants. Rocuronium and suxamethonium were responsible for the majority of 
Number of cases
Year Suxamethonium Rocuronium Vecuronium Atracurium of patient doses purchased was relatively stable across the ten years for suxamethonium, rocuronium and vecuronium. There was a steady increase in the amount of atracurium purchased, rising approximately threefold across the ten years, and there was a steady decrease in the quantity of pancuronium purchased. Mivacurium was purchased only in very small amounts and has not been included in the graph. Unfortunately purchasing data for the relaxants from the other hospitals was not available. Because only ten cases occurred at the Royal Adelaide Hospital, a statistical comparison between the anaphylactic reaction rate for each drug and Royal Adelaide Hospital purchasing data has not been made.
DISCUSSION
The most common cause of anaphylaxis during anaesthesia is a muscle relaxant 2,3,17-21 . Rocuronium reactions in total and when broken down by each of the three referral areas.
Thirty cross-reactions were identified. Where rocuronium was the index agent, 65% of patients demonstrated cross sensitivity with other muscle relaxants, in particular suxamethonium ( Table 2) . None of the patients who had a reaction to rocuronium had a demonstrated cross-reaction to pancuronium. When the index agent was suxamethonium, 29% of patients cross-reacted with another relaxant, the most common being rocuronium. In only one case there was a cross-reaction to pancuronium. No crossreaction was found to atracurium.
The number of cases of anaphylaxis confirmed annually varied from zero in 2000 with a maximum of six in 2001, 2006 and 2007. For both suxamethonium and rocuronium there was no obvious increase or decrease in trend across the ten years ( Figure 4 ). Figure 5 shows the muscle relaxant purchasing data for the Royal Adelaide Hospital. The proportion tABle 2 Cross-reactivity found with patients whose anaphylaxis was triggered by rocuronium and those whose anaphylaxis was triggered by suxamethonium. The most common cross-reactivity is between rocuronium and suxamethonium in both directions. 
Cross-reaction

Percentage of doses (vials) purchased
Year Suxamethonium Rocuronium Vecuronium Atracurium Pancuronium and suxamethonium were the most common agents triggering anaphylaxis in our population. Previously published data shows a similar pattern [1] [2] [3] 9, 10, 14, 17, 18 .
Our results show that there were no patients referred with a positive test result for pancuronium as the causative agent, although a positive skin test was obtained when looking for safe alternatives in one patient who reacted to suxamethonium. None of the referred cases had been given cisatracurium or mivacurium as part of their anaesthetic, and tests for these agents were not performed. Cisatracurium was not available in the Royal Adelaide Hospital during the audit period but was used in other public and private hospitals, although its use was relatively limited as it only received approval for use in Australia in 1997. Figure 3 indicates that the Royal Adelaide Hospital saw a larger proportion of anaphylactic reactions to suxamethonium than the other public and private hospitals. This may reflect a greater use of the drug due to a larger proportion of emergency cases and may also be influenced by the presence of less experienced trainees performing intubations.
In this audit rocuronium was most associated with anaphylaxis and this was accompanied by the highest rate of cross-reactivity with 65% of patients reacting to another muscle relaxant, most commonly suxamethonium. The second most common cause of relaxant anaphylaxis, suxamethonium, also showed a substantial rate of cross-reaction with almost onethird of cases reacting to another relaxant, most commonly rocuronium followed by vecuronium.
That in five cases atracurium caused anaphylaxis is surprising as it is a less used agent according to the Royal Adelaide Hospital's purchasing data. It is also interesting that only two cases of atracurium crossreactivity were identified, suggesting that these are unlikely to be histamine false-positives.
One of the aims of the audit was to see if any muscle relaxants were inherently safer or higher risk with respect to anaphylaxis. It has not been possible to obtain purchasing data from the referring hospitals apart from the Royal Adelaide Hospital, and the purchasing data from the Royal Adelaide Hospital cannot be extrapolated to all hospitals without making a number of assumptions. Previous publications have indicated that pancuronium and vecuronium cause anaphylaxis less frequently, and suxamethonium and atracurium cause anaphylaxis more commonly than would be expected from their market share [1] [2] [3] 10, 14, 18 . As only a small number of cases originated from the Royal Adelaide Hospital it has not been possible to statistically compare anaphylaxis with market share. However, our audit data do not appear to contradict the previously published data.
Since 2010 all public hospitals in South Australia have been using a common computer purchasing program. A future audit using these more complete data may allow for a more accurate comparison.
CONClUSION
In summary, the majority of positive intradermal tests to muscle relaxants were to rocuronium and suxamethonium. Where rocuronium was the index agent, 65% of patients cross-reacted with another relaxant. A total of 29% of patients with suxamethonium as their index agent demonstrated crossreaction with another relaxant.
